Kiniksa Pharmaceuticals (NASDAQ:KNSA) Reaches New 1-Year High - What's Next?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $30.60 and last traded at $30.35, with a volume of 37954 shares changing hands. The stock had previously closed at $30.23.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KNSA. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday. Wedbush reiterated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Stock Performance

The company has a market cap of $2.21 billion, a PE ratio of -215.77 and a beta of 0.06. The firm's 50 day moving average is $24.27 and its 200-day moving average is $21.91.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same quarter in the prior year, the company earned ($0.25) EPS. Kiniksa Pharmaceuticals's revenue was up 72.5% compared to the same quarter last year. On average, analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Mark Ragosa sold 18,299 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total value of $527,011.20. Following the transaction, the chief financial officer now directly owns 27,009 shares of the company's stock, valued at $777,859.20. This trade represents a 40.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Michael R. Megna sold 15,211 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $28.75, for a total transaction of $437,316.25. Following the transaction, the chief accounting officer now directly owns 32,546 shares in the company, valued at $935,697.50. The trade was a 31.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 391,014 shares of company stock worth $10,101,143 in the last ninety days. 54.57% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at about $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at about $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals during the first quarter worth about $42,000. Finally, Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals during the fourth quarter worth about $61,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.